JP2024509501A5 - - Google Patents
Info
- Publication number
- JP2024509501A5 JP2024509501A5 JP2023544261A JP2023544261A JP2024509501A5 JP 2024509501 A5 JP2024509501 A5 JP 2024509501A5 JP 2023544261 A JP2023544261 A JP 2023544261A JP 2023544261 A JP2023544261 A JP 2023544261A JP 2024509501 A5 JP2024509501 A5 JP 2024509501A5
- Authority
- JP
- Japan
- Prior art keywords
- hhla2
- seq
- amino acid
- acid sequence
- binder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026078333A JP2026119212A (ja) | 2021-01-28 | 2026-05-07 | 新規活性を持つｈｈｌａ２結合剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142832P | 2021-01-28 | 2021-01-28 | |
| US63/142,832 | 2021-01-28 | ||
| PCT/US2022/014423 WO2022165258A1 (en) | 2021-01-28 | 2022-01-28 | Hhla2 binding agents with novel activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026078333A Division JP2026119212A (ja) | 2021-01-28 | 2026-05-07 | 新規活性を持つｈｈｌａ２結合剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509501A JP2024509501A (ja) | 2024-03-04 |
| JP2024509501A5 true JP2024509501A5 (enExample) | 2025-02-04 |
Family
ID=82652818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544261A Pending JP2024509501A (ja) | 2021-01-28 | 2022-01-28 | 新規活性を持つｈｈｌａ２結合剤 |
| JP2026078333A Pending JP2026119212A (ja) | 2021-01-28 | 2026-05-07 | 新規活性を持つｈｈｌａ２結合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026078333A Pending JP2026119212A (ja) | 2021-01-28 | 2026-05-07 | 新規活性を持つｈｈｌａ２結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250270323A1 (enExample) |
| EP (1) | EP4284431A4 (enExample) |
| JP (2) | JP2024509501A (enExample) |
| KR (1) | KR20230135637A (enExample) |
| CN (1) | CN116981476A (enExample) |
| AU (1) | AU2022214939A1 (enExample) |
| BR (1) | BR112023014826A2 (enExample) |
| CA (1) | CA3207494A1 (enExample) |
| IL (1) | IL304584A (enExample) |
| MX (1) | MX2023008182A (enExample) |
| WO (1) | WO2022165258A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122161832A (zh) * | 2023-09-08 | 2026-06-05 | Nextpoint治疗公司 | 抗体-药物缀合物 |
| CN119841949B (zh) * | 2023-10-17 | 2026-06-05 | 科辉智药(深圳)新药研究中心有限公司 | 一种抗人hhla2的纳米抗体及其应用 |
| CN121005781A (zh) * | 2024-05-24 | 2025-11-25 | 合肥天港免疫药物有限公司 | 高亲和力b7h7抗体或其抗原结合片段及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015167948A1 (en) * | 2014-04-30 | 2015-11-05 | Albert Einstein College Of Medicine Of Yeshiva University | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies |
| TWI917306B (zh) * | 2017-07-06 | 2026-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
| MX2020010094A (es) * | 2018-04-06 | 2021-01-15 | Dana Farber Cancer Inst Inc | Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos. |
| CN111196852A (zh) * | 2018-11-16 | 2020-05-26 | 四川科伦博泰生物医药股份有限公司 | 抗tigit抗体及其用途 |
-
2022
- 2022-01-28 WO PCT/US2022/014423 patent/WO2022165258A1/en not_active Ceased
- 2022-01-28 BR BR112023014826A patent/BR112023014826A2/pt unknown
- 2022-01-28 MX MX2023008182A patent/MX2023008182A/es unknown
- 2022-01-28 CA CA3207494A patent/CA3207494A1/en active Pending
- 2022-01-28 EP EP22746752.9A patent/EP4284431A4/en active Pending
- 2022-01-28 JP JP2023544261A patent/JP2024509501A/ja active Pending
- 2022-01-28 US US18/263,313 patent/US20250270323A1/en active Pending
- 2022-01-28 KR KR1020237028708A patent/KR20230135637A/ko active Pending
- 2022-01-28 AU AU2022214939A patent/AU2022214939A1/en active Pending
- 2022-01-28 CN CN202280012137.1A patent/CN116981476A/zh active Pending
-
2023
- 2023-07-19 IL IL304584A patent/IL304584A/en unknown
-
2026
- 2026-05-07 JP JP2026078333A patent/JP2026119212A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002615A5 (enExample) | ||
| JP2022541435A5 (enExample) | ||
| JP2022527151A5 (enExample) | ||
| WO2022045247A1 (ja) | 抗切断型変異ｃａｌｒ－ｃｄ３二重特異性抗体及び医薬組成物 | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2024001073A5 (enExample) | ||
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| CN117062834A (zh) | Gpc3人源化抗体及其应用 | |
| JP2020528936A5 (enExample) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| WO2022061255A1 (en) | Specificity enchanced bispecific antibody (seba) | |
| JP2025510642A5 (enExample) | ||
| WO2023221935A1 (zh) | 结合pd-l1和cldn18.2的抗体及其用途 | |
| JP2025516590A5 (enExample) | ||
| WO2023222135A9 (en) | A method of treating solid tumor | |
| JP2024508597A5 (enExample) | ||
| KR20230156021A (ko) | Ror1 결합 단백질 및 이의 용도 | |
| AU2021231712A1 (en) | Anti-CD19 antibodies and methods of using and making thereof | |
| WO2024251051A1 (en) | Combination therapies involving claudin 18.2 antagonists for treatment of cancer | |
| US20240166756A1 (en) | Anti-CXCR2 Antibodies and Uses Thereof | |
| US20240383981A1 (en) | Uses of t cell engaging proteins in the treatment of cancer | |
| JP2023539883A5 (enExample) | ||
| KR20250069411A (ko) | 항 ceacam5 항체 및 이의 용도 | |
| JP2025508374A5 (enExample) | ||
| HK40120258A (en) | A method of treating solid tumor |